Large numbers of data show that the changes of expression and activity of SHP-2 are closely related to the pathogenesis of a variety of diseases, including hematopoiesis, Noonan syndrome, childhood leukemia, lung cancer, breast cancer, neuroblastoma, and autoimmune diseases [20–25]. Here, PTPN11 is linked to lung cancer.